Biotech news

Reset all filters
Geography
Company
Refine search
Federal Circuit upholds Inter-Cellular PTA delay
Americas
The US Court of Appeals for the Federal Circuit has ruled that delays resulting from challenges to patent examiners’ final decisions will be attributed to the applicant when calculating patent term adjustment.   23 September 2019
AG advises CJEU on rights of plant variety owners
Biotech
Advocate general Henrik Saugmandsgaard Øe has advised Europe’s highest court on the scope of protection held by owners of plant variety rights.   19 September 2019
Fed Circuit backs USPTO’s term adjustment for Mayo antibody patent
Americas
The US Court of Appeals for the Federal Circuit has affirmed the US Patent and Trademark Office’s patent term adjustment of a Mayo Foundation-owned patent.   18 September 2019
Americas
A couple who worked at Ohio-based research institute Nationwide Children’s Hospital have been charged with stealing trade secrets and then using the information to market products through their Chinese company.   17 September 2019
Americas
Taiwanese company JHL Biotech will stop developing biosimilar versions of Genentech’s drugs as part of a memorandum of understanding signed by the parties to end trade secrets litigation.   10 September 2019
Pharma
Held during Boston’s week-long Biotech festival, BioPharm America promises its 4,500 delegates excellent knowledge, networking, and deal opportunities, says Guadalupe Rodriguez of EBD Group.   10 September 2019
Americas
IP services company Clarivate Analytics has acquired patent sequence information provider SequenceBase to expand its search and analysis capabilities for the life sciences IP market.   9 September 2019
Asia
Indian drugmaker Lupin and German pharma company Boehringer Ingelheim have formed an alliance to develop a therapy for patients with difficult-to-treat cancers.   5 September 2019
Pharma
CAR-T cells have achieved hugely-positive outcomes in treating forms of cancer that are otherwise difficult to treat.   5 September 2019
Americas
US-based Vertex Pharmaceuticals has announced it will pay $950 million to acquire Semma Therapeutics, a biotechnology company focused on researching a cure for Type 1 diabetes.   4 September 2019